ALXO News & Events

ALX Oncology announced the appointments of Scott Garland as chairman of the board of directors and Michael Listgarten as general counsel, effective immediately. Garland succeeds Corey Goodman, who is stepping down as chairman and a member of the board. Most recently, Listgarten served as general counsel at RAPT Therapeutics.

ALX Oncology (ALXO) announced the appointment of Jeff Knight as chief development and operating officer, effective April 13. Most recently, he served as chief development and operating officer at Crinetics (CRNX).